Indium (111In) capromab pendetide
|Target||prostatic carcinoma cells|
|ATC code||V09IB04 (WHO)|
|(what is this?)|
Indium (111In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer. Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen (PSMA) from prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA. Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single photon emission computed tomography (SPECT).
Early trials with yttrium (90Y) capromab pendetide were also conducted.
- Manyak, M. J. (2008). "Indium-111 capromab pendetide in the management of recurrent prostate cancer". Expert Review of Anticancer Therapy. 8 (2): 175–122. doi:10.1586/14737188.8.131.52. PMID 18279057.
- WHO Drug Information
- Kahn, Daniel; J. Christopher Austin; Robert T. Maguire; Sara J. Miller; Jack Gerstbrein; Richard D. Williams (1999). "A Phase II Study of [90Y] Yttrium-Capromab Pendetide in the Treatment of Men with Prostate Cancer Recurrence Following Radical Prostatectomy". Cancer Biotherapy & Radiopharmaceuticals. 14 (2): 99. doi:10.1089/cbr.1999.14.99.